Single-dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain Fvs1

Clinical Cancer Research

Volumn 7, Issue 1, 2001, Pages 175-184

  Goel, A ^a   Augustine, S ^a   Baranowska Kortylewicz, J ^a   Colcher, D ^a   Booth, B J M ^a   Pavlinkova, G ^a   Tempero, M ^a   Batra, S K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; MONOCLONAL ANTIBODY CC49;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CANCER TRANSPLANTATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; RADIOIODINATION; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTIBODIES, NEOPLASM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; DOSE FRACTIONATION; FEMALE; GENETIC VECTORS; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035137345     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. A new era for radiolabeled antibodies in cancer?
2. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: A Phase II study
3. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
4. 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer
5. 2 anti-carcinoembryonic antigen MAb and AHSCR
6. European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
7. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy
8. Multicenter Phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
9. Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer. Correlation with computed tomography, surgery, histopathology, immunohistology, and human immune response
10. 131I]anti-B1 (anti-CD20) antibody
11. 67Cu-2IT-BATLym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma
12. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancer
13. 2
14. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG
15. Strategies for developing effective radioimmunotherapy for solid tumors
16. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions
17. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3
18. Experimental radioimmunotherapy
19. 2 in nude mice bearing human tumor xenografts
20. 2 as compared to intact antibodies in radioimmunotherapy of established human colon carcinoma grafted in nude mice
21. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy
22. 99mTc-labeled LL2-Fab′ (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma
23. Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2
24. Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides?
25. Recombinant antibody constructs in cancer therapy
26. Single-chain antigen-binding proteins
27. Medical applications of single-chain antibodies
28. In vivo tumor targeting of a recombinant single-chain antigen-binding protein
29. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
30. New protein engineering approaches to multivalent and bispecific antibody fragments
31. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv
32. Tumor localization of anti-CEA single-chain Fvs: Improved targeting by non-covalent dimers
33. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu
34. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody
35. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct
36. Divalent form of CC49 single-chain antibody constructs in Pichia pastoris: Expression, purification and characterization
37. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies
38. 131I-CC49 in colorectal cancer
39. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following α-interferon treatment
40. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma
41. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A Phase I trial
42. Protein measurement by Folin phenol
43. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
44. Single chain antibodies in pancreatic cancer
45. Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody
46. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine
47. The MIRD perspective 1999. Medical internal radiation dose committee
48. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure
49. Determinants of tumor blood flow: A review
50. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates
51. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy
52. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer
53. 131I-labeled monoclonal antibody CC49
54. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody
55. Experimental immunotherapy of human breast carcinomas implanted in nude mice with a mixture of monoclonal antibodies against human milk fat globule components
56. Biological considerations for radioimmunotherapy
57. New concepts in monoclonal antibody based radioimmunodiagnosis and radioimmunotherapy of carcinoma
58. 131I anti-CEA antibody in a colonic xenograft model
59. 2 fragments of monoclonal antiferritin in nude mouse model
60. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments
61. Improved tumor targeting with chemically cross-linked recombinant antibody fragments
62. Preparation of a trivalent antigen-binding construct using polyoxime chemistry: Improved biodistribution and potential for therapeutic application
63. Human monoclonal antibody homodimers. Effect of valency on in vitro and in vivo antibacterial activity
64. Monoclonal antibody homodimers: Enhanced antitumor activity in nude mice
65. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts
66. Radioimmunotherapy of solid tumors: A review "of mice and men"
67. 131I-labeled monoclonal antibodies
68. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts
69. 131I-labeled CC49 for therapy in a colon cancer xenograft model
70. Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: A biomathematical model
71. Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor
72. Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: Effects of dose escalation and repeated i.v. administration
73. Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability
74. Pharmacokinetics and biodistribution of a light-chain shuffled CC49 single-chain Fv antibody construct
75. Combined radioimmunotherapy and chemotherapy of human colon carcinoma grafted in nude mice, advantages and limitations
76. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice
77. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice
78. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents
79. 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model
80. 131I-labeled bivalent hapten
81. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity